introduction: silymarine extract is currently prescribed by some physicians for treatment of fatty liver disease. in the present study, the effect of administration of tablet containing silymarine extract on plasma homocysteine (hcy), folate, vitamin b12 and liver enzymes activity in non-alcoholic steatohepatitis (nash) was investigated. materials and methods: seventy-four patients (40 female a...

non-alcoholic steatohepatitis is a form of chronic hepatitis. fatty degeneration may involve liver focally or as a whole. the patient was a 41-year-old woman who was diabetic and admitted in buali hospital in ghazvin because of right flank pain, fever, vomiting and diarrhea. the patient was treated as pyelonephriris. liver function tests were as below: alt: 62 (40) ast: 54 (40), alkaline phosoh...

aim: the healthy ranges for serum alanine aminotransferase (alt) levels are less well studied. the aim of this study was to define the upper limit of normal (uln) for serum alt levels, and to assess factors associated with serum alt activity in apparently healthy blood donors. methods: a total of 1939 blood donors were included. alt measurements were performed for all cases using the same labor...

background : non-alcoholic steatohepatitis (nash) is a common liver disease that, in the absence of treatment may progress to cirrhosis. there is a strong association of nash with insulin resistance; thus insulin sensitizer drugs have been used for this disease. the aim of this study was to compare the effect of pioglitazone with metformin on liver transaminases, the homa index, and adiponectin...

Non-alcoholic steatohepatitis, one form of the non-alcoholic fatty liver disease spectrum, has been associated with obesity and lipid dysregulation. The patient usually presents with abnormal lipid and liver profiles. The most evidence based treatment for non-alcoholic steatohepatitis involves around weight loss, glycemic control and avoiding liver insulting drugs. Our current understanding of ...

Non-alcoholic steatohepatitis, one form of the non-alcoholic fatty liver disease spectrum, has been associated with obesity and lipid dysregulation. The patient usually presents with abnormal lipid and liver profiles. The most evidence based treatment for non-alcoholic steatohepatitis involves around weight loss, glycemic control and avoiding liver insulting drugs. Our current understanding of ...

Non-alcoholic steatohepatitis, one form of the non-alcoholic fatty liver disease spectrum, has been associated with obesity and lipid dysregulation. The patient usually presents with abnormal lipid and liver profiles. The most evidence based treatment for non-alcoholic steatohepatitis involves around weight loss, glycemic control and avoiding liver insulting drugs. Our current understanding of ...

BACKGROUND/AIMS Relationship between hepatic antioxidant paraoxonase 1 (PON1) activity, lipid peroxidation and liver injury was investigated in patients with non-alcoholic steatohepatitis. METHODS A total of 23 patients with non-alcoholic steatohepatitis (15 males, 8 females; mean age: 40.30+/-7.67 yrs) and 23 healthy controls (14 males, 9 females; mean age: 39.70+/- 8.78 yrs) were enrolled i...

BACKGROUND & AIMS The diagnosis of non-alcoholic steatohepatitis and fibrosis staging are central to non-alcoholic fatty liver disease assessment. We evaluated multiparametric magnetic resonance in the assessment of non-alcoholic steatohepatitis and fibrosis using histology as standard in non-alcoholic fatty liver disease. METHODS Seventy-one patients with suspected non-alcoholic fatty liver ...

â  â  background a substantial proportion of the mortality in patients with type 2 diabetes mellitus (t2dm) is related to non-alcoholic fatty liver disease (nafld) and its complications. insulin resistance is a major etiologic factor for the development of fatty liver. we aimed to study the prevalence of nafld among t2dm patients and its relation to insulin resistance. methods patients with t2d...